CRMD: CorMedix Inc. Company Profile & Statistics

CorMedix Inc. Profile

About

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog

Info & Links

CEO

Joseph Todisco

Headquarters

389 INTERPACE PKWY, SUITE 450
PARSIPPANY, NJ 07054, UNITED STATES

Auditor

CBIZ CPAs P.C.

Share holders

Employees

191

CorMedix Inc. Statistics

Valuation Measures

Market Capitalization²

584.47M

Enterprise Value

551.26M

Enterprise Value/EBITDA(ttm)

2.51

Price to Earnings Ratio(ttm)

3.94

Price to Sales(ttm)

1.46

Price to Book(mrq)

1.34

Price to Cash(ytd)

3.64

Profitability

Gross Margin(ttm)

87.63%

Operating Margin(ttm)

40.93%

Profit Margin(ttm)

48.80%

Return on Equity(ttm)

45.57%

Return on Invested Capital(ttm)

39.08%

Return on Assets(ttm)

24.76%

Income Statement

Revenue(ttm)

400.05M

Revenue Per Share(ttm)

5.10

Gross Profit(ttm)

343.38M

EBITDA(ttm)³

219.44M

Net Income Available to Common(ttm)

181.01M

Diluted EPS(ttm)

2.13

Share Statistics

Beta (5Y Monthly)

1.50

52-Week Change

-31.17%

S&P 500 52-Week Change

21.72%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

78.45M

Dividend Yield

0.00%

Float⁴

75.71M

% Held by Insiders

3.50%

% Held by Institutions

34.18%

Balance Sheet

Total Cash(mrq)

178.09M

Total Cash Per Share(mrq)

2.27

Total Debt(mrq)

144.88M

Total Debt/Equity(mrq)

33.15%

Current Ratio(mrq)

2.98%

Quick Ratio(mrq)

2.74%

Book Value Per Share(mrq)

5.58

Cash Flow

Operating Cash Flow Per Share(ytd)

0.46

Free Cash Flow(ytd)

41.65M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CRMD

CorMedix Inc.